Tocofersolan

• CAS: 9002-96-4
• Catalog Number: ACM9002964
• Category: Main Products
• Molecular Weight: 662.942
• Molecular Formula: C₃₉H₆₆O₈
• Synonyms: DL-A-TOCOPHEROL POLYETHYLENE GLYCOL SUCCINATE;DL-ALPHA-TOCOPHEROL POLYETHYLENE GLYCOL SUCCINATE;d-alpha-tocopheryl polyethylene glycol succinate;alpha-(4-((3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2h-1-benzopyran-6-yl)oxy)-1,4-dioxobutanol poly(ethylene glycol) succinate;tocofersolan;tocopherosolan;2-ethanediyl),.alpha.-[4-[[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzoPoly(oxy-1;4-dioxobutyl)-omega-hydroxy--trimethyltridecyl)-2h-1-benzopyran-6-yl)oxy)-
• IUPAC Name: Vitamin E-TPGS
• Boiling Point: 662.7ºC at 760mmHg
• Melting Point: 34-38°C
• Flash Point: 195.4ºC
• Density: 1.01g/cm³
• Appearance: Clear, colorless solid
• Exact Mass: 662.47600
• Stability: Stable under normal temperatures and pressures.

Case Study

Tocofersolan for Neuroprotection in Benzo[a]pyrene-Exposed Zebrafish Larvae

Holloway Z, et al. NeuroToxicology, 2021, 86, 78-84.

This study explored the neuroprotective potential of tocofersolan, a synthetic, water-soluble form of vitamin E, in larval zebrafish development under oxidative stress induced by benzo[a]pyrene (BaP). Zebrafish embryos were exposed from 5 to 120 hours post-fertilization to 5 μM BaP, with or without co-treatment with tocofersolan at concentrations ranging from 0.3 to 3 μM. The selected BaP concentration was sufficient to impair neural function without causing morphological abnormalities or lethality. Locomotor activity and photic responsivity were evaluated one day post-exposure using alternating 10-minute light/dark cycles to quantify neurobehavioral outcomes. BaP exposure resulted in significant locomotor hypoactivity, consistent with BaP-induced oxidative neurotoxicity. Notably, co-exposure with 1 μM tocofersolan effectively restored locomotor function to control levels, suggesting its role in mitigating oxidative damage and preserving neural development. This experiment underscores tocofersolan's application as a potential antioxidant rescue agent against PAH-induced neurotoxicity.

Tocofersolan for the Treatment of Vitamin E Deficiency in Fat Malabsorption Disorders

Cuerq C, et al. Journal of Lipid Research, 2018, 59(9), 1640-1648.

In a crossover clinical study, tocofersolan-a water-soluble derivative of RRR-α-tocopherol-was evaluated for its efficacy in correcting vitamin E deficiency in patients with abetalipoproteinemia (ABL) and chylomicron retention disease (CMRD), two rare genetic disorders associated with severe fat malabsorption. Seven patients (three with ABL, four with CMRD) received single oral doses of tocofersolan and α-tocopherol acetate, followed by plasma α-tocopherol measurements to assess bioavailability. Subsequently, both formulations were administered daily over a 4-month treatment period to assess long-term efficacy in restoring vitamin E levels.
The experimental design involved a detailed pharmacokinetic analysis, wherein plasma α-tocopherol concentrations were measured at specified time intervals after single oral administration. Tocofersolan demonstrated a markedly improved absorption profile in CMRD patients, with a bioavailability of 24.7%, compared to 11.4% for α-tocopherol acetate. In ABL patients, however, both formulations exhibited similarly low bioavailability (2.8% vs. 3.1%). After 4 months of continuous supplementation, steady-state plasma α-tocopherol concentrations showed no significant difference between formulations in either group. This study highlights the practical application of tocofersolan as an alternative therapeutic approach for managing vitamin E deficiency in lipid absorption disorders, emphasizing its enhanced intestinal uptake in conditions with partial lipid transport impairment such as CMRD.